文献速递精神分裂症与精神病性障碍会诊联络精神医学

GLP-1受体激动剂与精神分裂症合并2型糖尿病成人精神科住院及急诊就诊风险的关联

GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

加权回归显示,启动GLP-1受体激动剂与较低的精神科住院和急诊就诊风险相关。

要点

  • GLP-1受体激动剂启动与精神科住院风险低于未启动、DPP-4抑制剂启动和SGLT2抑制剂启动相关。
  • GLP-1受体激动剂启动与精神科急诊就诊风险低于未启动、DPP-4抑制剂启动和SGLT2抑制剂启动相关。
  • 结果提示代谢治疗药物可能附带精神科急性服务使用减少的获益,但需随机对照研究验证。

核心结论

  • 在精神分裂症合并2型糖尿病成人中,启动GLP-1受体激动剂与较低的精神科住院和急诊就诊风险相关。

关键数值与推荐

  • 暴露为启动GLP-1受体激动剂,对照为未启动、启动DPP-4抑制剂或启动SGLT2抑制剂。
  • 主要结局为精神科住院和精神科急诊就诊风险,采用逆概率加权和加权回归模型分析。
  • 随访从首次处方日期(T0)至2年、末次临床观察或观察期结束(2026年3月24日)中最早者。

临床怎么用

  • 对于有代谢管理指征的精神分裂症合并2型糖尿病成人,GLP-1受体激动剂可能带来精神科急性服务使用减少的次要获益。
  • 不应将GLP-1受体激动剂作为主要精神科治疗使用,其精神科疗效需随机对照和机制研究验证。

局限性

  • 可能存在残余混杂和选择偏倚,限制结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many individuals with schizophrenia have persistent psychotic symptoms despite antipsychotic treatment, and the disorder is associated with a disproportionately high burden of metabolic dysregulation. Whether GLP-1 receptor agonists are associated with psychiatric benefit alongside their metabolic effects remains unknown. We aimed to examine associations between GLP-1 receptor agonist initiation and psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes, compared with DPP-4 inhibitor initiation, SGLT2 inhibitor initiation, and non-initiation. METHODS: In this observational cohort study, we used electronic health record (EHR) data from the US NeuroBlu Data repository to construct a cohort of adults (≥18 years) with documented diagnosis of schizophrenia and comorbid type 2 diabetes. The exposure was the initiation of GLP-1 receptor agonists, compared with non-initiation or initiation of DPP-4 inhibitors or SGLT2 inhibitors. The index date, from Jan 1, 2018, was defined as the date of the first recorded psychiatric visit at which both a diagnosis of schizophrenia and comorbid type 2 diabetes were present in the participant's record. Time zero (T0) was the date of the first prescription of any of these agents between Jan 1, 2018, and Oct 1, 2025; for non-initiators, T0 was the index date. Participants contributed person-time from T0 until 2 years of follow-up, the last recorded clinical observation in the NeuroBlu Data repository, or the end of the observation period (March 24, 2026), whichever happened earliest. The main outcomes of interest included risk of psychiatric hospitalisation and psychiatric emergency department presentation. Inverse probability weighting was applied to balance demographic, clinical, and pharmacological covariates, and weighted regression models were used. Analyses were conducted using an intention-to-treat framework, whereby exposure status was defined according to the medication initiated at T0. FINDINGS: A total of 70 257 individuals met the inclusion criteria; mean age was 53·1 years [SD 12·32] and 33 882 [48·2%] were women. Among the 70 257 eligible individuals, 9093 (12·9%) initiated GLP-1 receptor agonists, 4968 (7·1%) initiated DPP-4 inhibitors, 5328 (7·6%) initiated SGLT2 inhibitors, and 50 868 (72·4%) were non-initiators. In weighted regression analyses, GLP-1 receptor agonist initiation was associated with a lower risk of psychiatric hospitalisation compared with non-initiation (weighted hazard ratio [HR] 0·76 [95% CI 0·71-0·82]), DPP-4 inhibitor initiation (0·82 [0·75-0·90]), and SGLT2 inhibitor initiation (0·83 [0·78-0·88]). GLP-1 receptor agonist initiation was also associated with a lower risk of emergency department presentation than non-initiation (0·71 [0·65-0·77]), DPP-4 inhibitor initiation (0·87 [0·80-0·95]), and SGLT2 inhibitor initiation (0·80 [0·73-0·88]). INTERPRETATION: GLP-1-based therapy initiation was associated with lower psychiatric acute-care use than non-initiation and initiation of DPP-4 or SGLT2 inhibitors in adults with schizophrenia and type 2 diabetes. Potential residual confounding and selection bias restrict generalisability of the results. The findings suggest that lower psychiatric acute-care use could be a favourable secondary benefit when GLP-1-based therapies are clinically indicated for metabolic management, although their use as primary psychiatric treatments require investigation in randomised and mechanistic studies. FUNDING: Synergy for the Development of Innovative Clinical Treatments in Schizophrenia (SYNDICAT) project (GNT2035912).

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Davoodian N, Williams LJ, Berk M, et al. GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data. Lancet Psychiatry. 2026. PMID: 42874603. doi:10.1016/S2215-0366(26)00276-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。